📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Avient Corporation operates as a formulator of material solutions in the United States, Canada, Mexico, Europe, South America, and Asia. The company operates in two segments, Color, Additives and Inks; and Specialty Engineered Materials. The Color, Additives and Inks segment offers custom color and additive concentrates in solid and liquid form for thermoplastics, dispersions for thermosets, and specialty inks; custom-formulated liquid system, such as polyester, vinyl, natural rubber and latex, polyurethane, and silicone; and proprietary inks. The company products are used in medical and pharmaceutical devices, food packaging, personal care and cosmetics, transportation, building products, wire and cable, recreational and athletic apparel, construction and filtration, outdoor furniture, healthcare, textiles and appliances, and industrial markets. The Specialty Engineered Materials segment provides specialty polymer formulations, services, and solutions for designers, assemblers, and processors of thermoplastic materials. It sells its products through direct sales personnel, distributors, and commissioned sales agents. The company was formerly known as PolyOne Corporation and changed its name to Avient Corporation in June 2020. Avient Corporation was founded in 1885 and is headquartered in Avon Lake, Ohio.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding AVNT

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Steve Cohen Point72 Asset Management	532.0K	$19.3M	0.02%	Mar 2026
Jim Simons Renaissance Technologies LLC	49.7K	$1.8M	0.00%	Mar 2026
Cathie Wood ARK Investment Management	2.4K	$86K	0.00%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific ~ Volatile 4 quarters analysed

Q2 2025

Mixed

Confident about operational execution (sales growth 0.6%, EPS up 5%, margins up 30bps, cost savings increased to $40m) but cautious on macro outlook ('customers remain in wait-and-see mode', 'consumer weakness across the globe', 'uncertainty still remains around trade policy').

Q3 2025

Cautious

Management led with a positive EPS beat in line with guidance but immediately tempered it with repeated references to "slightly weaker than anticipated sales", "subdued market demand", and "uncertain global macro environment". They stressed productivity gains and margin expansion as offsets, but explicitly described a "slow or no growth period" and a proactive "Plan B" for extended weakness. The language is disciplined and specific about execution, yet persistently hedged with downside qualifiers.

Q4 2025

Confident Specific

Management used strong, specific language: 'strong execution', '80 basis points of Adjusted EBITDA margin expansion', '14% Adjusted EPS growth', 'record high margins of 16.7%'. They provided concrete numbers and clear examples of innovation (GlideTech, non-PFAS, Dyneema debottlenecking). No hedging or defensive statements.

Q1 2026 latest

Confident Specific

Management repeatedly used phrases like 'disciplined execution', 'modestly ahead of expectations', 'well prepared', 'proven playbook', and 'net price positive' to convey confidence in navigating inflation and supply disruptions. They highlighted specific volume and price data, e.g., packaging up low single digits, and gave explicit raw material cost ranges.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis appears slightly strengthened by management's demonstrated pricing power and operational discipline in a volatile environment, with Q1 slightly ahead and a clear playbook for managing raw material inflation. However, the maintained guidance (not raised) and explicit uncertainty about second-half demand, especially in consumer and industrial end markets, tempers conviction. The key to watch in the next quarter is whether price increases stick without significant volume loss, and whether the pull-forward of demand in Q2 leads to a subsequent dip in Q3. Also monitor the trajectory of packaging (upbeat) vs. consumer/industrial (soft) to gauge end-market recovery. Overall, the call supports a cautious positive thesis but with a wide range of outcomes depending on macro conditions.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific ~ Volatile 4 quarters Full tone analysis in Intelligence →

📊 MIXED Avient Q1 2026 EPS $0.83; guides FY EBITDA $555-$585M; packaging resilient.

Revenue & Profitability

First quarter 2026 adjusted EPS was $0.83. Full-year fiscal 2026 guidance includes adjusted EBITDA of $555 million to $585 million, adjusted EPS of $2.93 to $3.17, and free cash flow exceeding $200 million. For the second quarter, management expects adjusted EPS of $0.89. The first half performance is trending slightly ahead of expectations.

Outlook

Management sees elevated uncertainty in the second half 2026 due to Middle East conflicts and inflationary pressures. They currently maintain full-year guidance but expect organic sales growth in both segments and total company margin expansion in Q2. Packaging demand is improving, while consumer and industrial end markets remain subdued. The first half is modestly ahead of plan.

Growth Drivers

Key growth vectors include electronics and high-performance computing (expected >$40 million in 2026 sales, doubling in three years), defense, healthcare, and packaging share gains. Geographically, Asia grew 2% in Q1, driven by packaging and telecom. Packaging is expected to deliver mid- to high-single-digit growth in Q2, led by EMEA. Share gains are occurring in food/beverage packaging, building & construction, and healthcare drug delivery.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

First-quarter adjusted EBITDA margins expanded 20 basis points year-over-year, with CAI up 40 bps and SEM down 40 bps due to unfavorable mix. Productivity initiatives and pricing more than offset wage inflation and lower volumes. Management expects total company margin expansion in Q2 and uses productivity levers (sourcing, footprint, SG&A) to manage profitability.

Key Risks

Management flagged high uncertainty for the second half due to Middle East geopolitical events, raw material inflation, and potential demand weakness in consumer and industrial end markets. Supply chain disruptions and inflationary pressures on hydrocarbons and freight are near-term challenges. The impact of customer pre-buying and inventory rebalancing also creates visibility risk.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Q2 2026 results exceeded expectations with strong volume-driven growth, record margins, and robust performance in Asia and key end markets. Full-year guidance was raised for adjusted EBITDA, EPS, and free cash flow, with continued focus on innovation, debt reduction, and margin expansion.

Q1 2026 Q1 2026 2026-05-07

Q1 adjusted EPS exceeded expectations, with margin expansion and strong cash focus despite subdued early demand. Full-year guidance is maintained amid ongoing inflation and geopolitical volatility, with growth driven by pricing, innovation, and share gains in key markets.

Q4 2025 Q4 2025 2026-02-12

Strong execution in 2025 led to record Adjusted EBITDA margins, robust EPS growth, and significant debt reduction, driven by innovation and productivity, especially in defense, healthcare, and telecom. 2026 guidance anticipates continued margin expansion and free cash flow, with investments focused on defense capacity and no planned M&A.

Q3 2025 Q3 2025 2025-11-05

Q3 adjusted EPS met guidance despite weaker sales, with margin expansion driven by productivity and innovation in healthcare and defense. Outlook for Q4 remains cautious, with flat to slightly down sales expected, but strong performance in defense, healthcare, and telecom anticipated.

Q2 2025 Q2 2025 2025-08-01

Q2 2025 saw modest organic sales growth and margin expansion, with strong performance in healthcare and defense offsetting consumer weakness. Debt reduction and innovation initiatives remain on track, while full-year guidance anticipates stable demand and continued margin gains.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.